Increasing unhealthy habits is primarily aiding growth for the global antiulcerant drugs market. Increasing population in the developing countries, busy lifestyle, rising disposable income, advancements in 3D printing, IoT, and big data are the other contributing factors for the industry growth rate.
High prevalence of diabetes that leads to diabetic foot ulcers is estimated to boost the industry revenue generation till 2027. However, tightening government regulations and policies related to drug patents may hamper the global antiulcerant drugs market size in the coming seven years.
Global antiulcerant drugs market is segregated on the basis of type as, proton pump inhibitors, H2 receptor antagonists, gastric mucosal protective drugs, antibiotics, antacids and prostaglandin agonists. The industry is divided by disease as Stomach Ulcers, Leg Ulcer, Peptic Ulcers, Esophageal Ulcer, Bleeding Ulcer, Refractory Ulcer, Stress Ulcer, Mouth Ulcers, Venous Stasis Ulcers, Neuropathic Ulcers, Arterial (Ischemic) Ulcers, and Pressure Ulcers.
Global antiulcerant drugs market report provides geographic analysis covering regions such as North America, Europe, Asia Pacific, and Rest of World. The antiulcerant drugs market for each region is further segmented for major countries including U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
AstraZeneca, Allergan, Daewoong Pharmaceutical, Eisai, Takeda Pharmaceutical Company, Valeant, Zydus, Shire, and Meritage Pharma are among the major players in the global antiulcerant drugs market share. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Antiulcerant Drugs Market is segmented as below:
Antiulcerant Drugs Market, By Product
Antiulcerant Drugs Market, By Disease
Antiulcerant Drugs Market, By Region
The report covers:
Report scope:
Global antiulcerant drugs market report scope includes detailed study covering underlying factors influencing the industry trends.
The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.
The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global antiulcerant drugs market share. Major industry players with significant revenue share include AstraZeneca, Allergan, Daewoong Pharmaceutical, Eisai, Takeda Pharmaceutical Company, Valeant, Zydus, Shire, and Meritage Pharma.
Reasons to Buy this Report:
Customization:
Customized report as per the requirement can be offered with appropriate recommendations
Below are our New Reports :-
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Increasing incidence of ulcer
4.2.2. Unhealthy eating habits
4.3. Restraints
4.3.1. Rising physical fitness awareness
4.4. Opportunities
4.4.1. Merger and acquisitions among industry players
4.5. Challenges
4.5.1. Unfavourable laws for drug patents
4.5.2. Rising trade protectionism
5. Antiulcerant Drugs Market, By Type
5.1. Key Points
5.2. Proton pump inhibitors
5.3. H2 receptor antagonists
5.4. Gastric mucosal protective drugs
5.5. Antibiotics
5.6. Antacids
5.7. Prostaglandin agonists
6. Antiulcerant Drugs Market, By Disease
6.1. Key points
6.2. Stomach Ulcers
6.3. Leg Ulcer
6.4. Peptic Ulcers
6.5. Esophageal Ulcer
6.6. Bleeding Ulcer
6.7. Refractory Ulcer
6.8. Stress Ulcer
6.9. Mouth Ulcers
6.10. Venous Stasis Ulcers
6.11. Neuropathic Ulcers
6.12. Arterial (Ischemic) Ulcers
6.13. Pressure Ulcers
7. Competitive Landscape
7.1. Introduction
7.2. Recent Developments
7.2.1. Mergers & Acquisitions
7.2.2. New Product Developments
7.2.3. Portfolio/Production Capacity Expansions
7.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
7.2.5. Others
8. Company Profile
8.1. AstraZeneca
8.1.1. Company Overview
8.1.2. Product/Service Landscape
8.1.3. Financial Overview
8.1.4. Recent Developments
8.2. Allergan
8.2.1. Company Overview
8.2.2. Product/Service Landscape
8.2.3. Financial Overview
8.2.4. Recent Developments
8.3. Daewoong Pharmaceutical
8.3.1. Company Overview
8.3.2. Product/Service Landscape
8.3.3. Financial Overview
8.3.4. Recent Developments
8.4. Eisai
8.4.1. Company Overview
8.4.2. Product/Service Landscape
8.4.3. Financial Overview
8.4.4. Recent Developments
8.5. Takeda Pharmaceutical Company
8.5.1. Company Overview
8.5.2. Product/Service Landscape
8.5.3. Financial Overview
8.5.4. Recent Developments
8.6. Valeant
8.6.1. Company Overview
8.6.2. Product/Service Landscape
8.6.3. Financial Overview
8.6.4. Recent Developments
8.7. Zydus
8.7.1. Company Overview
8.7.2. Product/Service Landscape
8.7.3. Financial Overview
8.7.4. Recent Developments
8.8. Shire
8.8.1. Company Overview
8.8.2. Product/Service Landscape
8.8.3. Financial Overview
8.8.4. Recent Developments
8.9. Meritage Pharma
8.9.1. Company Overview
8.9.2. Product/Service Landscape
8.9.3. Financial Overview
8.9.4. Recent Developments
The Antiulcerant Drugs Market is segmented as below:
Antiulcerant Drugs Market, By Product
Antiulcerant Drugs Market, By Disease
Antiulcerant Drugs Market, By Region
SUBSCRIBE TO OUR NEWSLETTERS
